Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [31] Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
    Lantuejoul, Sylvie
    Damotte, Diane
    Hofman, Veronique
    Adam, Julien
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S89 - S101
  • [32] Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients
    Ilie, Marius
    Juco, Jonathan
    Huang, Lingkang
    Hofman, Veronique
    Khambata-Ford, Shirin
    Hofman, Paul
    CANCER CYTOPATHOLOGY, 2018, 126 (04) : 264 - 274
  • [33] Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer
    Cui, Shaohua
    Su, Xinying
    Dong, Lili
    Qian, Jialin
    Ye, Lin
    Zhang, Tianwei
    Fu, Haihua
    Han, Hulin
    Huang, Jiaqi
    Yao, Yihong
    Gu, Yi
    Jiang, Liyan
    JOURNAL OF CANCER, 2017, 8 (19): : 4075 - 4082
  • [34] Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy
    Mamesaya, Nobuaki
    Muramatsu, Koji
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Sugino, Takashi
    Shimizu, Tetsuo
    Gon, Yasuhiro
    Takahashi, Toshiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 659 - 669
  • [35] Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer
    Nagasaki, Yusuke
    Taki, Tetsuro
    Nomura, Kotaro
    Tane, Kenta
    Miyoshi, Tomohiro
    Samejima, Joji
    Aokage, Keiju
    Ohtani-Kim, Seiyu Jeong-Yoo
    Kojima, Motohiro
    Sakashita, Shingo
    Sakamoto, Naoya
    Ishikawa, Shumpei
    Suzuki, Kenji
    Tsuboi, Masahiro
    Ishii, Genichiro
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (07): : 1158 - 1168
  • [36] Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
    Garg, Gaurav
    Prasad, Kuruswamy Thurai
    Singh, Navneet
    Gupta, Parul
    Muthu, Valliappan
    Das, Ashim
    Bal, Amanjit
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (06) : 398 - 405
  • [37] Prevalence of programmed death ligand-I in patients diagnosed with non-small cell lung cancer in Lebanon
    Fakhri, Ghina
    Akel, Reem
    Khalifeh, Ibrahim
    Chami, Hassan
    Ali, Adel Hajj
    Al Assaad, Majd
    Atwi, Haneen
    Kadara, Humam
    Tfayli, Arafat
    SAGE OPEN MEDICINE, 2021, 9
  • [38] Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
    Kumar, Manish
    Guleria, Bhupesh
    Swamy, Shivashankar
    Soni, Sneha
    LUNG INDIA, 2020, 37 (02) : 145 - 150
  • [39] Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors A protocol for systematic review and meta-analysis
    Li, Honglin
    Han, Deting
    Feng, Xiaoteng
    Yu, Wenjun
    Xu, Tongtong
    Ma, Tao
    Song, Lucheng
    MEDICINE, 2020, 99 (32) : E21613
  • [40] Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer
    Daverio, Matteo
    Patrucco, Filippo
    Gavelli, Francesco
    Airoldi, Chiara
    Sciortino, Giusy
    Chiaramonte, Claudia
    Rena, Ottavio
    Balbo, Piero E.
    Boldorini, Renzo L.
    CANCER CYTOPATHOLOGY, 2020, 128 (08) : 580 - 588